Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in STEMI patients
NCT06081803Phase 3Active, not recruiting
- Sponsor
- Sejong General Hospital
- Start
- Dec 2020
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of evolocumab in ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by Sejong General Hospital. Primary endpoint: Myocardial infarct size at 1 month. Started Dec 2020; status: active, not recruiting.
02
Drugs
evolocumab
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT06081803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06081803.